Clinical trials: Treatment Resistant Major Depression Disorder
Depression, Major Depressive Disorder
eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
This pilot randomized controlled trial seeks: (1) to determine the preliminary efficacy of our modernized collaborative care intervention for depression in improving the diabetes risk markers of hemoglobin A1c and insulin…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT04437485
- Testing
- Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Indiana University
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
- Trial name
- NARSAD (NCT03283670)
- Testing
- Nitrous Oxide 25%, Nitrous Oxide 50%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A Study of Ketamine in Patients With Treatment-resistant Depression
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
- Trial name
- NCT01627782
- Testing
- Ketamine
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder
Ketamine in Adolescents With Treatment-Resistant Depression
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
- Trial name
- NCT02078817
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment-resistant Depression
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity.
- Trial name
- NCT04680910
- Testing
- Propofol, Electroencephalography (EEG), Slow-Wave Activity
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Deep Brain Stimulation for Treatment Resistant Depression
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant…
- Trial name
- NCT00367003
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that…
- Trial name
- NCT01920555
- Testing
- Ketamine
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression, Major Depressive Disorder
The UTHealth Ketamine Project
The primary objective of this study is to determine the effectiveness of serial infusions of intravenous (IV) ketamine in adults with treatment resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02882711
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Major Depressive Disorder
Rapid Antidepressant Effects of Leucine
This randomized double-blind placebo-controlled crossover study seeks to evaluate the antidepressant effect of L-leucine, an essential amino acid, in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT03079297
- Testing
- L-Leucine, Maltodextrin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Texas Southwestern Medical Center